Immunotherapeutic trials are already underway in other cancer types with agents directed against several of these including EPCAM (63), glycoprotein A33; GPA33 (64, 65), mucin 1, cell surface associated; MUC1 (66) and melanoma antigen; MAGE (67) proteins. This evidence concerns the gene GPA33 and cancer.